Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis
Benedikt Simbrunner(Austrian Academy of Sciences), Thomas Reiberger(ERN GUARD-Heart), Lukas Hartl(Medical University of Vienna), Bernhard Scheiner(Medical University of Vienna), Benedikt Hofer(Medical University of Vienna), Albert Friedrich Stättermayer(Medical University of Vienna), Rodrig Marculescu(Medical University of Vienna), Mathias Jachs(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Michael Trauner(Medical University of Vienna), David Bauer(Austrian Academy of Sciences)
Cited by 26
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
|Journal of Hepatology|2024|239